Sign In
Buy GRTX
$0.100
-0.0010 (-0.99%)
At Close: Jun 03, 2026
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference
12:00pm, Thursday, 30'th Jul 2020
MALVERN, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, prop
Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?
06:35pm, Wednesday, 22'nd Jul 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Galera Phase 2 Trial, And Other News: The Good, Bad And Ugly Of Biopharma
05:43pm, Wednesday, 15'th Jul 2020
Galera completed enrollment for its Phase 1b/2a clinical trial of avasopasem manganese or GC4419. Albireo enrolled the first patient in its Phase 3 clinical trial of Odevixibat.
Topline safety and efficacy data to be reported in the second half of 2020MALVERN, Pa., July 13, 2020 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical c
Hedge Funds Are Selling Galera Therapeutics, Inc. (GRTX)
06:55pm, Wednesday, 10'th Jun 2020
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F
Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin
12:00pm, Friday, 29'th May 2020
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfor
Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease
08:05pm, Monday, 18'th May 2020
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfor
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
11:00am, Tuesday, 12'th May 2020
Galera Therapeutics, Inc. (GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transfor
Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference
12:00pm, Tuesday, 05'th May 2020
MALVERN, Pa., May 05, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program
08:15pm, Thursday, 30'th Apr 2020
MALVERN, Penn., April 30, 2020 -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of.
Galera Therapeutics (NASDAQ:GRTX) Upgraded at Zacks Investment Research
06:02am, Thursday, 30'th Apr 2020
Galera Therapeutics (NASDAQ:GRTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com r
Galera Therapeutics (NASDAQ:GRTX) Stock Rating Lowered by Zacks Investment Research
05:50am, Thursday, 23'rd Apr 2020
Galera Therapeutics (NASDAQ:GRTX) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to
Galera Therapeutics (NASDAQ:GRTX) Stock Rating Upgraded by Zacks Investment Research
05:12am, Wednesday, 22'nd Apr 2020
Galera Therapeutics (NASDAQ:GRTX) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The firm prese
Galera Therapeutics (NASDAQ:GRTX) Raised to "Buy" at Zacks Investment Research
05:44am, Saturday, 18'th Apr 2020
Zacks Investment Research upgraded shares of Galera Therapeutics (NASDAQ:GRTX) from a hold rating to a buy rating in a research note published on Wednesday morning, Zacks.com reports. Zacks Investment
